PURPOSE: Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The exclusive expression of E7, a viral oncogene, in infected cells makes this protein an ideal target for immunotherapy. We recently reported on the results of a trial in women with cervical carcinoma-in-situ using HspE7, a protein vaccine consisting of full length HPV16 E7 linked to a heat shock protein from M. bovis. The stimulating effects of HspE7 on specific cytotoxic T lymphocytes have been demonstrated in vitro and in (pre-)clinical trials. The induction of a B-cell response by HspE7 and its association with clinical outcome is unknown, and is the purpose of this study. EXPERIMENTAL DESIGN: We measured the serum IgG levels against HPV16 E7 and HPV16 and -18 VLPs using a multiplexed Luminex based assay in 57 women with CIS who received the HspE7 vaccine. RESULTS: Vaccination with HspE7 results in a modest, yet maintained increase in HPV16 E7 specific IgG levels. While not significant, increased HPV16 E7 IgG levels appear to be correlated with a positive therapeutic effect. Women who were previously treated for recurrent disease (by LEEP) had significantly higher HPV16 E7 IgG levels compared with subjects without recurrent disease (p=0.01). In women with recurrent disease, higher IgG levels correlated with complete pathological response. CONCLUSIONS: This study suggests that IgG levels could potentially be used as a marker for response to a therapeutic vaccine. Further translational investigations of the 'priming' of local immune responses using extirpative procedures should be explored. Copyright 2009 Elsevier Inc. All rights reserved.
PURPOSE: Infection with oncogenic human papillomaviruses has been linked to the development of cervical neoplasia and cancer. The exclusive expression of E7, a viral oncogene, in infected cells makes this protein an ideal target for immunotherapy. We recently reported on the results of a trial in women with cervical carcinoma-in-situ using HspE7, a protein vaccine consisting of full length HPV16 E7 linked to a heat shock protein from M. bovis. The stimulating effects of HspE7 on specific cytotoxic T lymphocytes have been demonstrated in vitro and in (pre-)clinical trials. The induction of a B-cell response by HspE7 and its association with clinical outcome is unknown, and is the purpose of this study. EXPERIMENTAL DESIGN: We measured the serum IgG levels against HPV16 E7 and HPV16 and -18 VLPs using a multiplexed Luminex based assay in 57 women with CIS who received the HspE7 vaccine. RESULTS: Vaccination with HspE7 results in a modest, yet maintained increase in HPV16 E7 specific IgG levels. While not significant, increased HPV16 E7 IgG levels appear to be correlated with a positive therapeutic effect. Women who were previously treated for recurrent disease (by LEEP) had significantly higher HPV16 E7 IgG levels compared with subjects without recurrent disease (p=0.01). In women with recurrent disease, higher IgG levels correlated with complete pathological response. CONCLUSIONS: This study suggests that IgG levels could potentially be used as a marker for response to a therapeutic vaccine. Further translational investigations of the 'priming' of local immune responses using extirpative procedures should be explored. Copyright 2009 Elsevier Inc. All rights reserved.
Authors: Yevgeniy Y Studentsov; Mark Schiffman; Howard D Strickler; Gloria Y F Ho; Yuk-Ying Susana Pang; John Schiller; Rolando Herrero; Robert D Burk Journal: J Clin Microbiol Date: 2002-05 Impact factor: 5.948
Authors: J G Joyce; J S Tung; C T Przysiecki; J C Cook; E D Lehman; J A Sands; K U Jansen; P M Keller Journal: J Biol Chem Date: 1999-02-26 Impact factor: 5.157
Authors: Jill Koshiol; Lisa Lindsay; Jeanne M Pimenta; Charles Poole; David Jenkins; Jennifer S Smith Journal: Am J Epidemiol Date: 2008-05-15 Impact factor: 4.897
Authors: Allan Hildesheim; Rolando Herrero; Sholom Wacholder; Ana C Rodriguez; Diane Solomon; M Concepcion Bratti; John T Schiller; Paula Gonzalez; Gary Dubin; Carolina Porras; Silvia E Jimenez; Douglas R Lowy Journal: JAMA Date: 2007-08-15 Impact factor: 56.272
Authors: J Visser; H W Nijman; B-N Hoogenboom; P Jager; D van Baarle; E Schuuring; W Abdulahad; F Miedema; A G van der Zee; T Daemen Journal: Clin Exp Immunol Date: 2007-11 Impact factor: 4.330
Authors: Aagje G Bais; Ilse Beckmann; Patricia C Ewing; Marinus J C Eijkemans; Chris J L M Meijer; Peter J F Snijders; Theo J M Helmerhorst Journal: Mediators Inflamm Date: 2007 Impact factor: 4.711